Regulation and marketing of cannabidiol-containing products in European countries. Pharmacists’ knowledge in Bulgaria

References

• Top 5 trends in the pharmaceutical industry in 2019. MasterControl Inc.; [cited 2019 Nov]. Available from: https://www.mastercontrol.com/learning-center/pharmaceutical/top-5-trends-in-the-pharmaceutical-industry-in-2019
   Google Scholar
• Medical marijuana market worth over $55 billion by 2024: Global Market Insights, Inc. GlobeNewswire; [cited 2018 Aug 22]. Available from: https://globenewswire.com/news-release/2018/08/22/1555007/0/en/Medical-Marijuana-Market-worth-over-55-billion-by-2024-Global-Market-Insights-Inc.html
   Google Scholar
• The global cannabis market continues to grow as medical cannabis legalization spreads. Cision, PR Newswire; [cited 2018 Nov 13]. Available from: https://www.prnewswire.com/news-releases/the-global-cannabis-market-continues-to-grow-as-medical-cannabis-legalization-spreads-816722673.html
   Google Scholar
• Medical use of cannabis and cannabinoids: Questions and answers for policymaking. EMCDDA, Lisbon; [cited 2018 Dec]. Available from: https://www.emcdda.europa.eu/system/files/publications/10171/20185584_TD0618186ENN_PDF.pdf
   Google Scholar
• Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019;10:697–614.
   PubMed Web of Science ®Google Scholar
• Marinotti O, Sarill M. Differentiating full-spectrum hemp extracts from CBD isolates: implications for policy, safety and science. J Diet Suppl. 2020;17(5):517–526.
   PubMedGoogle Scholar
• CANNABIDIOL (CBD) Critical Review Report Expert Committee on Drug Dependence Fortieth Meeting Geneva, 4–7 June 2018. Available from: https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf
   Google Scholar
• The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press for the National Academies of Sciences Engineering and Medicine, Washington, DC; 2017.
   Google Scholar
• Office of the Commissioner. Public Health Focus—FDA and Marijuana: Questions and Answers. 2018. Available from: https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm421168.htm
   Google Scholar
• CANNABIDIOL (CBD) Pre-Review Report Agenda Item 5.2 Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6–10 November 2017. Available from: https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf
   Google Scholar
• Wiffen P. The cannabis conundrum. Eur J Hosp Pharm. 2020;27(1):1. [32064080]
   PubMedGoogle Scholar
• NICE. NICE guidance on cannabis based medicinal products. Available from: https://www.nice.org.uk/guidance/ng144
   Google Scholar
• Medicinal cannabis and derivatives: a legal analysis of the options, their limitations, and current practice in the EU. EMCDDA, ELDD Comparative Study, May 2002. Available from: http://eldd.emcdda.org/databases/eldd_comparative_analyses.cfm
   Google Scholar
• Monograph Epidyolex® [cannabidiol] for seizures associated with Lennox-Gastaut syndrome [adjunctive treatment with clobazam] (specialist use only), and seizures associated with Dravet syndrome [adjunctive treatment with clobazam] (specialist use only). Joint Formulary Committee. British National Formulary (online), London. BMJ Group and Pharmaceutical Press; 2020. Available from: https://about.medicinescomplete.com/publication/british-national-formulary/
   Google Scholar
• Specification sheet (version: January 2019. Product: Cannabis flos, ssp. sativa, variety Bediol (hemp flowers). Office of Medicinal Cannabis. CIBG Ministerie van Volksgezondheid, Welzijn en Sport. Available from: https://english.cannabisbureau.nl/
   Google Scholar
• Tilray Medical Cannabis Products Card. Tilray; 2020. Available from: https://www.tilray.ca/en/drops
   Google Scholar
• Krcevski-Skvarc N, Wells C, Häuser W. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. Eur J Pain. 2018;22(3):440–454.
   PubMed Web of Science ®Google Scholar
• Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018;3(1):152–161.
   PubMedGoogle Scholar
• Kathmann M, Flau K, Redmer A, et al. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006;372(5):354–361.
   PubMed Web of Science ®Google Scholar
• Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018; 19(3):833.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci. 2015;16(1):30–42.
   PubMed Web of Science ®Google Scholar
• Do Val-da Silva RA, Peixoto-Santos JE, Kandratavicius L, et al. Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy. Front Pharmacol. 2017;8:131. [28367124]
   PubMed Web of Science ®Google Scholar
• Massi P, Solinas M, Cinquina V, et al. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013;75(2):303–312.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Kuzontkoski PM, Groopman JE, et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10(7):1161–1172.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly ME, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–4805.
   PubMed Web of Science ®Google Scholar
• Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131–1141.
   PubMed Web of Science ®Google Scholar
• Piñeiro R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene. 2011;30(2):142–152.
   PubMed Web of Science ®Google Scholar
• Fasinu PS, Phillips S, ElSohly MA, et al. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy. 2016;36(7):781–796.
   PubMed Web of Science ®Google Scholar
• Deng L, Ng L, Ozawa T, et al. Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. J Pharmacol Exp Ther. 2017;360(1):215–224.
   PubMed Web of Science ®Google Scholar